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Abstract
The pro-apoptotic p53 target Noxa is a BH3-only protein that antagonizes the function of selected anti-apoptotic Bcl-2
family members. While much is known regarding the transcriptional regulation of Noxa, its posttranscriptional regulation
remains relatively unstudied. In this study, we therefore investigated whether Noxa is regulated by microRNAs. Using
a screen combining luciferase reporters, bioinformatic target prediction analysis and microRNA expression profiling, we
identified miR-200c as a negative regulator of Noxa expression. MiR-200c was shown to repress basal expression of Noxa, as
well as Noxa expression induced by various stimuli, including proteasomal inhibition. Luciferase reporter experiments
furthermore defined one miR-200c target site in the Noxa 39UTR that is essential for this direct regulation. In spite of the
miR-200c:Noxa interaction, miR-200c overexpression led to increased sensitivity to the clinically used proteasomal inhibitor
bortezomib in several cell lines. This apparently contradictory finding was reconciled by the fact that in cells devoid of Noxa
expression, miR-200c overexpression had an even more pronounced positive effect on apoptosis induced by proteasomal
inhibition. Together, our data define miR-200c as a potentiator of bortezomib-induced cell death. At the same time, we
show that miR-200c is a novel negative regulator of the pro-apoptotic Bcl-2 family member Noxa.
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Introduction
Death induced by the intrinsic mitochondrial pathway is
initiated by perturbation of the mitochondrial membrane, and
proceeds via release of cytochrome c and other apoptogenic
factors from the intermembrane space of this organelle. This
process is tightly regulated by the anti- and pro-apoptotic members
of the Bcl-2 family [1]. Cytochrome c release in response to
various types of cellular stress is suggested to occur via pores
formed by homo and hetero-oligomers of the pro-apoptotic Bcl-2
family members Bak and Bax [2]. The actual ratio of anti- to pro-
apoptotic Bcl-2 family members constitutes a sensor and sets the
threshold of susceptibility to apoptosis for the cell. That the
relative abundance of anti-apoptotic and pro-apoptotic regulators
also critically influences tumorigenesis is illustrated by the
recurring perturbation of this balance in cancer [3]. Consequently,
the expression of Bcl-2 family members is normally tightly
regulated at multiple levels including transcriptional activation
and proteasomal degradation [1].
In recent years, microRNAs have emerged as important
regulators of gene expression. MicroRNAs are 21–23 bp long
non-coding RNAs that function mainly through targeting the
39UTR of specific genes and thereby inhibiting the translation of
their encoded protein or degrading the target mRNA [4,5]. With
their ability to regulate multiple genes simultaneously, microRNAs
have fundamental roles in such diverse processes as proliferation,
apoptosis and differentiation. Furthermore, many microRNAs,
such as those of the miR-15, let-7, or miR-17 families have been
shown to be deregulated in cancer, resulting in the altered
expression of target genes important for tumor development [6].
Some Bcl-2 family members have been shown to be regulated
by microRNAs, such as Bcl-2, which is regulated by miR-15/16
and miR-148a, [7,8,9] and Mcl-1, which is regulated by miR-29
[10]. However, for many of the Bcl-2 family members, including
the pro-apoptotic p53 target gene Noxa, it is unknown whether
microRNA regulation takes place. Like other BH3-only proteins,
Noxa has the capacity to bind and neutralize pro-survival Bcl-2
family members. However, it has a restricted binding pattern and
mainly interacts with Mcl-1 [11]. Among other things, this
interaction leads to proteasomal degradation of Mcl-1 [12,13],
which in turn has been shown to be a prerequisite for apoptosis
in response to for example UV irradiation [14].
Given the ability of Noxa to fine-tune apoptotic signaling in
response to various stimuli, and that Noxa protein induction is
necessary for cell death to occur following treatment with some
cytotoxic cancer drugs [13], we set out to investigate if Noxa is
regulated by microRNAs. Any given gene is generally predicted to
be regulated by many different microRNAs [15]. One major
obstacle in microRNA research is that the numerous bioinformatic
tools available for target prediction invariably give a large set of
false positive results [16]. Therefore, we made use of a luciferase-
based screening method to pick out the most relevant microRNAs
that target Noxa. Cloning the 39UTR of Noxa downstream of
a luciferase reporter and introducing this construct into cells
allowed us to determine to what degree the reporter activity is
repressed in different tissues. This analysis was then complemented
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pointed the critical regulatory part(s) of the 39UTR. Finally, the
combined results were then compared with existing microRNA
expression profiling data [17] to identify candidate microRNA(s)
that might account for the differential luciferase activity. Using this
screening system we identified miR-200c as a new regulator of
Noxa. MiR-200c was shown to repress both basal and stress-
induced Noxa protein expression. Surprisingly, enforced miR-
200c expression at the same time led to increased bortezomib-
induced apoptosis. This apparent discrepancy was reconciled by
the finding that in cells devoid of Noxa expression, miR-200c
caused an even greater increase in apoptosis. These data suggest
that miR-200c potentiates apoptosis induced by proteasomal
inhibitors but that it concomitantly represses Noxa which leads to
an attenuated apoptotic induction.
The data in this study define miR-200c as a novel regulator of
Noxa and more generally show that microRNA-induced pheno-
types must always be viewed as the complex results of a large
number of occurring individual microRNA:mRNA target inter-
actions.
Materials and Methods
Constructs, Inhibitors and Cloning
The miR-200c cluster expression construct was created by
nested PCR cloning using the pcDNA
TM 3.3 TOPOH TA Cloning
Kit (Invitrogen). As first round primers miR200c-F1 (59-GAT-
GAGGGTGGGTAAATCGG-39) and miR200c-R1 (59-AGG-
GACTGGGTTAATCTGCT-39) were used. Nested primers were
miR200c-F2 (59-CTGCTTGGACTGCAACCT-39) and
miR200c-R2 (59-GTCTCCTTCCCATTGTTCCC-39). The se-
quence of the cloned insert was verified in its entire length by
sequencing. qRT-PCR was used to confirm that miR-200c was
properly processed following plasmid transfection. The empty
pcDNA-3.3-TOPO vector was used as a negative control in all
transfection experiments. The full length (approximately 1.6 kb)
Noxa 39UTR was cloned using the primers Noxa-UTR-F1 (59-
CGAGTGTGCTACTCAACTCAG-39) and Noxa-UTR-R1 (59-
CAGAGGATGTCTGCTGATGG-39) as first round primers and
Noxa-UTR-F2(XhoI) (59-CTCGAGTGACTGCAT-
CAAAAACTTGCATGA-39) and Noxa-UTR-R2 (59- CACA-
GAAAAGAACAGTGAAAACT-39) as nested primers. The XhoI
restriction site in the Noxa-UTR-F2(XhoI) primer allowed for
directional subcloning into the pMIR-REPORT
TM (Ambion) and
psiCHECK
TM-2 (Promega) luciferase vectors. The Noxa 39UTR
deletion mutants psiCHK2-Noxa-DR1 and psiCHK2-Noxa-DR2
were created by using Noxa-UTR-R1(NotI) ((59-
GCGGCCGCGGAACTTTCATTCTAGATGAG-39) and
Noxa-UTR-R2(NotI) (59-GCGGCCGCCTGAGTATAA-
CATTTCAGT-39) respectively as reverse primers for cloning.
The NotI restriction site in the reverse primers allowed for
directional subcloning into the psiCHECK
TM-2 vector. The seed
sequence mutant psiCHK2-Noxa-Mut construct was created using
the QuikChange II Site Directed Mutagenesis Kit (Stratagene).
The Noxa overexpression plasmid was constructed by amplifying
the Noxa coding region from a pool of cell line cDNAs using the
KAPA2G Fast PCR mix (KAPABiosystems) with the primers
Noxa-F (GGACTGTTCGTGTTCAGCTC) and Noxa-R
(TTTCCATCTAAAGTGACTACAACC). Amplicons were gel-
purified and cloned into pcDNA3.3 using the pcDNA
TM 3.3
TOPOH TA Cloning Kit (Invitrogen). The wild type sequence of
the Noxa open reading frame in the construct was verified by
sequencing.
Oligonucleotides and Chemicals
Pre-miR-control (AM17110) and pre-miR-200c (PM11714)
were purchased from Ambion. The miR-200c anti-miR
TM
inhibitor (AM11714) and anti-miR
TM Negative Control #1
(AM17010) were obtained from Ambion. Noxa siRNA oligos
(59-GUAAUUAUUGACACAUUUC-39) and control oligos tar-
geting green fluorescent protein (59-CAAGCUGACCCUGAA-
GUUC-39) were purchased from Eurofins MWG and have been
described previously [18,19]. Bortezomib (VelcadeH) was from
Janssen-Cilag. MG132 was obtained from Calbiochem. Doxoru-
bicin was purchased from MEDA AB.
Bioinformatic Sequence Analysis
MiRNAs potentially targeting the 39UTR of Noxa were
predicted using TargetScan (http://www.targetscan.org/) miRan-
da (http://www.microrna.org/microrna/home.do) and PicTar
(http://pictar.mdc-berlin.de/). In order to qualify as a possible
Noxa regulator, a microRNA had to be predicted to have at least
one microRNA target site in the Noxa 39UTR according to at
least two out of three prediction algorithms. MicroRNA expression
data was obtained from microRNA.org (http://www.microrna.
org/).
Cell Lines, Transfections and Treatments
MCF7, HEK293 and U2OS cells, all originally obtained from
American Type Culture Collection (ATCC) (http://www.
lgcstandards-atcc.org/), were maintained in Dulbecco’s Modified
Medium (DMEM/High Modified, Hyclone) containing 10% FBS,
2 mM glutamine, 100 U/ml penicillin, and 100 g/ml streptomy-
cin. HCT116 cells were grown in McCoy’s 5A medium (with L-
glutamine, GIBCO) supplemented with 10% FBS, 100 U/ml
penicillin, and 100 g/ml streptomycin. HCT116 wild type and
DICER1 knockout cells [20] were kindly provided by B Vogelstein
and K Kinzler (John Hopkins University and Howard Hughes
Medical Institute). siRNA oligos and pre-miRNA oligos were
transfected using HiPerFect reagent (Qiagen), according to the
manufacturer’s instructions. Transfections of miRNA inhibitors
and cotransfections of plasmids and pre-miRNA oligos were
performed using Lipofectamine 2000 (Invitrogen). For plasmid
transfection experiments, cells were transfected with TransITH-
LT1 Transfection Reagent (Mirus) or GeneJuiceH Transfection
Reagent (Novagen) according to the manufacturers’ protocol.
Figure 1. MiR-200c is a candidate Noxa-regulating microRNA. (A) The Noxa 39UTR is repressed in MCF7 cells. The pMIR-REPORT (upper panel)
and psiCHECK2 (lower panel) vectors with the full length Noxa 39UTR downstream of luciferase or empty vector controls were introduced into the
indicated cell lines. Luciferase activity was normalized to the activity of an external Renilla luciferase plasmid (upper panel) or to an internal Firefly
luciferase (lower panel). (B) Expression profiling of microRNAs predicted to target the Noxa 39UTR. (C) The repressive element is located in the distal
part of the Noxa 39UTR. The full length Noxa 39UTR luciferase plasmid or the indicated deletion mutants were introduced into MCF7 cells and
luciferase activity was measured as in (A). A schematic representation of the different 39UTR constructs used in this study is also shown. The location
of target sites of the three Noxa-regulating candidates is included in the scheme. (D) Expression of Noxa inversely correlates with that of miR-200c.
MiR-200c expression was determined by qRT-PCR analysis in the indicated cell lines. Expression was normalized to that of the small nucleolar RNA
RNU48 (upper panel). Protein extracts were prepared in parallel and subjected to immunoblotting for endogenous Noxa (lower panel). GAPDH was
used as a loading control. Protein size in kilodaltons (kDa) is also shown.
doi:10.1371/journal.pone.0036490.g001
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miRNA oligos or 200 nM miRNA inhibitors were transfected per
6-well, if not otherwise stated. Generally, cells were transfected,
incubated for 24 hours and then treated with the indicated drug
for the indicated time period.
Western Blot Analysis and Antibodies
Cells were lysed in NP-40 buffer (150 mM NaCl, 1% Nonidet
P-40, 50 mM Tris pH 8.0) containing protease and phophatase
inhibitors (Roche) and western blot analysis was performed as
described previously [21]. The following primary antibodies were
used: mouse monoclonal against Noxa (Calbiochem), rabbit
polyclonal against GAPDH (Abcam), rabbit polyclonal against
cleaved caspase 3 (Asp175, Cell Signaling) and rabbit polyclonal
against cleaved PARP (Asp214, Cell Signaling). As secondary
antibodies HRP-conjugated anti-rabbit and anti-mouse antibodies
(Cell Signaling) were used.
Quantitative Real-time PCR (qRT-PCR)
Total RNA was extracted from indicated cell lines using Trizol
reagent (Life Technologies) and reverse transcribed using Super-
script II (Invitrogen) with random primers. Real-time PCR for
Noxa (primers: Noxa-F 59-ACTGTTCGTGTTCAGCTC-39 and
Noxa-R 59-GTAGCACACTCGACTTCC-39, [22]) was per-
formed using the Power SYBRH Green PCR Master Mix (Applied
Biosystems) in triplicate measurements on a 7900 HT Fast Real-
time PCR system (Applied Biosystems). Samples were quantified
using three point standard curves for each primer pair. Values
were normalized to the relative quantity of GAPDH (primers:
GAPDH-F 59-AGCCGAGCCACATCGCT-39 and GAPDH-R
59-GCAACAATATCCACTTTACCAGAGT-39). MiR-200c was
detected with Applied Biosystems TaqMan miRNA assays
(Product ID 002300). RNU48 (Product ID 001006) was used as
an internal standard. Relative quantification of microRNA
expression level was performed using the comparative Ct method,
22(DCtsample–DCtcontrol).
Luciferase Reporter Assays
Luciferase reporter assays were carried out using the Dual-




vectors containing the full-length, wild-type Noxa 39UTR or
mutant versions were used for transfections. The psiCHECK
TM-2
vector encodes an additional Firefly luciferase that allows for
normalization of transfection. With the pMIR-REPORT
TM
vector a separate Renilla luciferase plasmid was cotransfected for
normalization. 20 ng of respective 39UTR reporter plasmid was
cotransfected with 480 ng microRNA-encoding plasmid in 24-well
plates.
Assessment of Apoptosis by Annexin V and Propidium
Iodide Stainings
Redistribution of plasma membrane phosphatidyl serines was
assessed using Annexin V FLUOS (Boehringer Mannheim)
according to the manufacturer’s protocol. Annexin V and
propidium iodide (PI) stainings were performed and analyzed
using a FACScalibur flow cytometer (Becton Dickinson) with Cell
Quest Software as previously described [23].
Results
Luciferase-based Screening Identifies miR-200c as
a Potential Regulator of Noxa
In order to evaluate whether Noxa is regulated by microRNAs,
we first analyzed Noxa protein levels in HCT116 cells lacking
DICER1 (HCT116
DICER12/2), an RNase III enzyme required for
microRNA processing. Noxa protein was increased in HCT116
DI-
CER12/2 as compared to wild type cells, suggesting that Noxa
expression indeed is under the influence of microRNA regulation
(Figure S1). In order to identify which microRNAs that regulate
Noxa, we first cloned the entire Noxa 39UTR into the pMIR-
REPORT vector downstream of luciferase. This vector was
introduced into MCF7, HEK293 and U2OS cells and luciferase
activity was measured. As can be seen in Figure 1A, luciferase
expression was potently reduced in MCF7 cells while no repression
was observed in the other cell lines. In order to exclude the
possibility that this difference simply reflected differential usage of
the promoter driving luciferase in the different cell lines, the Noxa
39UTR was also cloned into the psiCHECK2 luciferase vector.
Using this construct, a similar result was obtained (Figure 1A, lower
panel). This raised the possibility that one or several microRNAs
that are expressed in MCF7 cells, but not in HEK293 or U2OS
cells, regulate Noxa expression. We proceeded to compile the
expression of all microRNAs predicted to target Noxa according
to the TargetScan, PicTar and miRanda algorithms (Figure 1B
and Materials and Methods). Notably, miR-141, miR-200c and
miR-375 displayed moderate to high levels of expression in MCF7
cells with little or no expression in HEK293 and U2OS. In order
to examine the relative impact of these three microRNAs on Noxa
regulation, luciferase reporter truncation mutants with progres-
sively shorter UTRs were created and introduced into MCF7 cells.
Figure 1C shows that luciferase activity was restored already with
the longest deletion mutant, indicating that the repressive element
is located in the distal 0.5 kb of the Noxa 39UTR. Of the three
candidate microRNAs, only miR-200c has a predicted target site
in the distal part of the Noxa 39UTR (Figure 1C). These results
strongly suggest that miR-200c regulates the Noxa 39UTR.
Finally, the differential expression of miR-200c in the three cell
lines was confirmed by qRT-PCR and was found to inversely
correlate with that of endogenous Noxa protein expression
(Figure 1D).
In conclusion, by making use of a luciferase-based screening
method together with microRNA expression profiling we could
identify miR-200c as a high-probability Noxa-regulating micro-
RNA.
Noxa is a Direct Target of miR-200c
The Noxa 39UTR contains one miR-200c target site that is
evolutionarily conserved down to armadillo (Dasypus novemcinctus)
(Figure 2A). In order to examine whether miR-200c regulates
Noxa, we mutated the seed region of this site, which is thought to
interfere with microRNA binding (Figure 2B). When cotransfect-
Figure 2. MiR-200c directly targets the Noxa 39UTR. (A) The extent of evolutionary conservation of the predicted miR-200c target site in the
Noxa 39UTR is shown. Outlined box demarks region complimentary to the seed sequence of miR-200c. (B) Specific mutations introduced at the miR-
200c target position in the Noxa 39UTR reporter. (C) The indicated constructs were introduced into HEK293 cells and luciferase activity was measured.
The luciferase ratio between the Renilla and Firefly of the empty vector transfection was adjusted to 1. (D) Luciferase reporter experiments were
performed as in Figure 1A with the wild-type Noxa 39UTR or the seed sequence mutant reporter constructs. The luciferase ratio between the Renilla
and Firefly of the wild type Noxa 39UTR vector transfection was adjusted to 1.
doi:10.1371/journal.pone.0036490.g002
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luciferase expression was decreased by around 50%. On the other
hand, the mutated vector (psiCHK2-Noxa-Mut) was completely
refractory to miR-200c-mediated repression (Figure 2C). These
results indicate that miR-200c directly targets Noxa and that this
regulation is dependent on one single target site located in the
distal part of the Noxa 39UTR. We next introduced the wild type
and mutated vector respectively into the cell lines used for the
initial screening. As can be seen in Figure 2D, a clear derepression
was observed with the mutant construct in MCF7 cells (with high
miR-200c expression), while little or no change in luciferase
activity was seen in the other cell lines with low or absent miR-
200c.
These results show that Noxa is a direct target of miR-200c and
that miR-200c is a major determinant of 39UTR-mediated Noxa
regulation.
miR-200c Downregulates Noxa Expression
We transfected HEK293 cells, which have low endogenous
miR-200c expression levels, with a vector encoding the miR-200c
cluster and analyzed Noxa protein levels at different timepoints
following transfection. As seen in Figure 3A, miR-200c over-
expression resulted in a clear downregulation of Noxa expression
at all timepoints analyzed. MicroRNA qRT-PCR was used to
confirm proper miR-200c processing following plasmid trans-
fection (Figure S2). Since the miR-200c cluster encodes both miR-
200c and miR-141, we also transfected a pre-miR-200c oligonu-
cleotide to investigate whether miR-200c expression alone is
sufficient to repress Noxa. Expression of the pre-miR-200c
oligonucleotide caused a clear downregulation of Noxa in several
cancer cell lines (Figure 3B and data not shown). MicroRNAs
repress gene expression by promoting RNA degradation and, to
a lesser extent, by inhibiting translation [5]. Overexpression of the
miR-200c cluster led to a significant downregulation of Noxa
mRNA levels as measured by qRT-PCR (Figure 3C). This
suggests that miR-200c indeed causes mRNA degradation of
Noxa. Under unstressed conditions, Noxa levels in cells are
generally very low, but are known to increase under conditions of
cellular stress [13]. Therefore, we assessed whether miR-200c can
modulate Noxa levels when Noxa is induced by proteasomal
inhibition. HEK293 cells were transfected with the miR-200c
cluster or an empty control vector and subsequently treated with
the proteasomal inhibitor MG132. As can be seen in Figure 3D,
induction of Noxa protein was attenuated in cells with over-
expressed miR-200c. Again, overexpression of the pre-miR-200c
oligonucleotide resulted in a similar decrease in Noxa protein
levels upon proteasomal inhibition (Figure 3D, right panel). This
effect was not dependent on cell type as miR-200c-mediated
repression of induced Noxa was evident also in HCT116 cells
(Figure S3).
Together these results demonstrate that miR-200c can down-
regulate Noxa RNA and protein under both normal conditions
and during cellular stress caused by proteasomal inhibition.
Noxa is Repressed by miR-200c Under Normal Conditions
In order to further examine whether the miR-200c-Noxa
interaction takes place when miR-200c is expressed at endogenous
levels, we made use of an inhibitor that binds miR-200c and
prevents it from binding to its targets. When introduced into
MCF7 cells a small, but consistent, increase in Noxa protein levels
was observed (Figure 4A and data not shown). A similar picture
emerged when cells were treated with MG132, again confirming
that the miR-200c-mediated regulation takes place both under
normal conditions and when Noxa is induced by exogenous stress
(Figure 4B). Taken together, these results suggest that Noxa is
regulated by endogenous miR-200c.
miR-200c Potentiates Proteasome Inhibitor-mediated
Cell Death
Given the effect of miR-200c on Noxa, we hypothesized that it
could modulate cellular sensitivity to apoptosis. We therefore
Figure 3. MiR-200c represses Noxa protein under both normal conditions and during cellular stress. (A) HEK293 cells were transfected
with a plasmid encoding the miR-200c microRNA cluster or an empty vector control. Cells were collected at indicated timepoints, whole cell extracts
were prepared and subjected to immunblotting for Noxa. (B) The indicated cell lines were transfected with pre-miR-200c or pre-miR-control oligos for
48 hours, whole cell extracts were prepared and analyzed for Noxa protein expression. (C) HEK293 cells were transfected with the indicated
expression constructs for 24 and 48 hours respectively, and Noxa mRNA expression was determined by qRT-PCR analysis. Noxa mRNA expression was
normalized to that of GAPDH. (D) HEK293 cells were transfected with indicated expression constructs (left panel) or oligonucleotides (right panel). 24
hours post-transfection, cells were treated with the indicated concentration of MG132 for an additional 3 or 24 hours, and processed for Noxa
immunoblotting as in (A). GAPDH was used as a loading control in all immunoblotting experiments. Protein size in kilodaltons (kDa) is also shown.
doi:10.1371/journal.pone.0036490.g003
Figure 4. Noxa is repressed by miR-200c under normal
conditions. (A) MCF7 cells were treated with miR-200c-specific
inhibitors or control inhibitors for 48 hours and Noxa protein was
analyzed as in Figure 3A. (B) MCF7 cells were treated with miR-200c-
specific inhibitors or control inhibitors. 24 hours post-transfection, cells
were treated with 1 mM MG132 for an additional 24 hours, and
processed for Noxa immunoblotting. Bands were quantified using
ImageJ software by normalizing the intensities for Noxa with GAPDH.
Protein size in kilodaltons (kDa) is also shown.
doi:10.1371/journal.pone.0036490.g004
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proteasome inhibitor bortezomib. This clinically used drug was
chosen since it has been shown that Noxa induction is important
for bortezomib-induced cell death [19,24,25]. Treatment of
HCT116 cells with clinically relevant doses of bortezomib led to
a time- and dose-dependent induction of Noxa protein (Figure S4).
As can be seen in Figure 5A, overexpression of miR-200c in
HCT116 cells treated with bortezomib led to a downregulation of
Noxa at all doses. Surprisingly, at the same time miR-200c
overexpression resulted in increased bortezomib-induced apoptosis
as assessed by immunoblotting for cleaved caspase 3 and cleaved
PARP (Figure 5A). In order to directly test how apoptosis
induction is affected by miR-200c overexpression, Annexin V/PI
staining was performed on HCT116 left untreated or treated with
bortezomib. Again, in both cases miR-200c overexpression led to
increased cell death, as compared to a scrambled pre-miR control
oligonucleotide (Figure 5B–C). A similar result was obtained in the
HEK293 cell line (data not shown). Also, this effect was not
restricted to proteasome inhibition, as cells treated with the DNA-
damaging drug doxorubicin showed increased apoptosis induction
upon miR-200c overexpression as well (data not shown). Since the
effects of miR-200c on Noxa and cell death induced by
bortezomib apparently contradict one another, we went on to
examine the effect of miR-200c on apoptosis in a setting without
Noxa expression. Therefore, we knocked down Noxa expression in
bortezomib-treated HCT116 cells using siRNA oligos. Knock-
down of Noxa led to an expected decrease in both Noxa protein
levels and proteasome inhibitor-induced apoptosis as measured by
Annexin V/PI staining (Figure 6A). Interestingly, when Noxa was
knocked down, miR-200c overexpression had an even more
pronounced effect on apoptosis induction. Indeed, in cells
transfected with control siRNA oligos, miR-200c overexpression
led to a 33% increase in apoptosis, as compared to cells transfected
with scrambled pre-miRs. In contrast, in cells with Noxa knocked
down the increase in apoptosis was 78% (Figure 6A). To further
investigate the relationship between miR-200c, Noxa and
bortezomib-induced cell death, we went on to ectopically express
a Noxa construct lacking the miR-200c target site (Figure S5).
When Noxa was overexpressed in cells left untreated with
bortezomib, only a minor effect on apoptosis could be observed
(Figure 6B, left panel). However, overexpression of Noxa potenti-
ated the positive effect of miR-200c on bortezomib-induced
apoptosis (Figure 6B, 71% versus 97% increase in apoptosis),
showing that artificially maintaining high Noxa levels in cells
increases the pro-apoptotic effects of miR-200c even further. In
summary, these data show that miR-200c sensitizes cells to
bortezomib treatment. However, at the same time it represses
Noxa, which leads to an attenuated bortezomib response.
Discussion
In this study we identify and validate miR-200c as a regulator of
the proapoptotic BH3-only member Noxa. Much is known
regarding the transcriptional regulation of Noxa. Several types
of cellular stress, such as DNA damage and hypoxia, lead to Noxa
induction in both a p53-dependent and independent fashion [13].
However, nothing has so far been reported concerning possible
microRNA regulation of Noxa. The identification of miR-200c as
a Noxa regulator was facilitated by a methodology that combines
a luciferase-based screening with mining of microRNA expression
data (Figure 1). This method is broadly applicable to the
identification of other microRNA:target interactions.
Obviously, other mechanisms than microRNAs exist that
regulategeneexpressionthroughthe39UTR.Severalrecentstudies
have demonstrated the importance of for example RNA-binding
proteins in posttranscriptional gene regulation [26,27,28]. Howev-
er, it has also been shown that in many cases there is extensive
interplaybetweenmicroRNAsandRNA-bindingproteins[29].For
example, miR-16 is necessary for the regulated turnover of AU-rich
element (ARE) containing mRNAs by the ARE-binding protein
tristetraprolin [30]. The fact that microRNA-mediated gene
repression makes up a substantial part of 39UTR-mediated
regulation was substantiated in a recent report investigating the
impact or shortened 39UTRs on oncogenic transformation. When
isoformsofvarying39UTRlengthoftheIMP-1oncogenewereused
in soft-agar colony formation assays, it was demonstrated that the
shorter isoforms were more oncogenic than the longer ones.
Importantly, this difference in transformation ability was mostly
attributed to loss of miRNA targeting, since microRNA target site
mutants yielded significantly enhanced transformation from the
longer isoforms [31]. One advantage with our method is that one is
not restricted to the cell lines used in the current study and it is of
course straightforward to change and expand the selection of cell
lines to a set that is optimal for a given target gene. Furthermore, as
more expression data is emerging, especially given the amounts of
information originating from the recently developed mass sequenc-
ing technologies, more and more tissues will be available for
consideration. Using a set of broadly used cancer cell lines, the
method allowed us to relatively quickly limit the number of possible
candidates and eventually end up on a true microRNA:target
interaction. The interaction was validated using a series of
experiments. First, overexpression of miR-200c led to dramatically
reduced Noxa levels in several cancer cell lines. Importantly, this
regulation occurred both in unstressed cells and cells exposed to
proteasomalinhibitors(Figures3,5andS3).ThatmiR-200cdirectly
targetsthe39UTRofNoxaatadefinedevolutionarilyconservedsite
was established using luciferase assays (Figure 2A–C). Finally, with
the help of specific miR-200c inhibitors we could show that Noxa is
normally under repression from endogenous miR-200c (Figure 4).
The miR-200 family of microRNAs (also known as the miR-8
family) consists of 5 members (miR-200a, miR-200b, miR-200c,
miR-141 and miR-429) expressed from two genomic locations.
They can be subdivided into two major groups that differ slightly
with regard to seed sequences and that have partly overlapping but
distinct sets of targets [32]. Several studies have reported that the
miR-200 microRNAs are potent regulators of epithelial-to-mesen-
chymal transition (EMT), a process that occurs during embryonic
development, wound healing and cancer metastasis [33]. During
EMT, epithelial cells acquire a more mesenchymal phenotype with
increasedmotilityandinvasivenessanddecreasedcell-celladhesion.
A key event during this transition is the loss of the epithelial marker
E-cadherin. MiR-200 family members have been shown to target
the transcription factors ZEB1 and ZEB2 that normally repress the
Figure 5. MiR-200c potentiates proteasome inhibitor-mediated cell death. (A) HCT116 cells were transfected with pre-miR-200c or pre-miR-
control oligos for 24 hours, treated with indicated concentrations of bortezomib for an additional 24 hours and processed for immunoblotting for
GAPDH, Noxa, cleaved PARP and cleaved caspase 3. Protein size in kilodaltons (kDa) is also shown. (B) HCT116 cells were transfected with pre-miR-
200c or pre-miR-control oligos for 48 hours and apoptosis was assessed by Annexin V/PI staining and FACS analysis. (C) HCT116 cells were treated
with 20 nM bortezomib as in (A) and apoptosis was assessed by Annexin V/PI staining and FACS analysis. Graphs show the mean of percentages of
Annexin V-positive cells, including PI-positive and PI-negative, from three independent experiments.
doi:10.1371/journal.pone.0036490.g005
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200 microRNAs help to maintain the cell in an epithelial state
[33,34,35]. It is known that EMT is intimately linked to cancer
development and that metastasizing cells undergo a process that is
very similar to EMT. However, cancer cells can also undergo the
reverse process, mesenchymal-to-epithelial transition (MET), when
colonizing distant sites in the body following extravasation. In light
of this it is perhaps not surprising that a complex picture emerges
with regard to cancer and miR-200. While many tumor types, such
as advanced breast cancer and clear cell carcinoma, show reduced
miR-200 levels, some other malignancies instead display over-
expressed miR-200 levels [33]. One speculative possibility is that
downregulationofmiR-200occursinsometumorswhenthecancer
cells become invasive and that this is followed by miR-200
upregulation in distant metastases that undergo MET.
While the novel miR-200c target Noxa is dispensable for certain
types of cell death, it is crucial for cell death in response to
proteasomal inhibition [19,24,25,36,37,38]. The proteasome in-
hibitorbortezomib(PS-341,VelcadeH)hasbeendemonstratedtobe
clinically beneficial in the treatment of multiple tumor types,
including myeloma and mantle cell lymphoma [39,40]. We
therefore chose to study its impact in relation to miR-200c. The
observed effects of miR-200c on Noxa and cell death induced by
bortezomib and other agents might at first appear counterintuitive.
Why would miR-200c potentiate apoptosis and repress Noxa at the
sametime?Onepossiblereasonisthatisamatterofthreshold.MiR-
200c keeps Noxa in check to prevent premature or excessive
apoptosis to occur. Once Noxa is induced to high enough levels
following cellular stress, the interaction between miR-200c and
NoxabecomeslessrelevantandothermiR-200ctargetsplayamore
important role. Indeed, several targets have been described that
could explain the pro-apoptotic effect of miR-200c, such as FAP-1
[41], PLCc1[32]and the above-mentioned ZEB1[42].Inlinewith
this, miR-200c has been described to potentiate apoptosis in
response to CD95 signaling and microtubule-targeting agents
[41,43]. Also, it is possible that the miR-200c:Noxa interaction
playsamoredominantroleinothertissuesorwhenNoxaisinduced
by other stimuli. One has to bear in mind that the phenotypic effect
ofagivenmicroRNAisdictatedbythesumtotalexpressionofallits
potential targets. Yet another possibility would be that Noxa for
some reason has an anti-apoptotic effect in our systems. However,
without Noxa expression, the positive effect of miR-200c on
apoptosis becomes even more pronounced (Figure 6A), indicating
that Noxa indeed potentiates cell death induced by bortezomib. In
linewiththis,ectopicexpressionofaNoxaconstructunresponsiveto
miR-200c regulation led to potentiation of miR-200c-mediated
apoptosis induction (Figure 6B). We thus have a situation where the
pro-apoptotic effect of miR-200c is partially counteracted by its
repressive effect on Noxa. Interestingly, a similar scenario was
described for miR-128. It apparently induces apoptosis in
HEK293T cells while at the same time it directly represses the
pro-apoptotic Bax protein [44].
In conclusion, we have identified miR-200c as an apoptosis-
regulatingmicroRNAthatrepressesNoxa.Thedatapresentedhave
implicationsfortheunderstandingofapoptosisingeneral,andNoxa
regulation in particular. Furthermore, it can also help explain the
mechanism behind bortezomib resistance in different tumors.
Supporting Information
Figure S1 Protein extracts were prepared from HCT116
DICER1 wild type and knockout cells and analyzed for
Noxa protein levels by immunoblotting. GAPDH was used
as a loading control.
(TIF)
Figure S2 HEK293 cells were transfected with the miR-
200c cluster expression vector or an empty vector
control. 48 hours post-transfection, cells were collected and
processed for TaqMan qRT-PCR analysis. MiR-200c expression
was normalized to that of the small nucleolar RNA RNU48 using
the comparative Ct method. The expression level in mock-
transfected cells is set to 1.
(TIF)
Figure S3 HCT116 cells were transfected with pre-miR-
200c or pre-miR-control oligos. 24 hours post-transfection,
cells were treated with the indicated concentrations of MG132 for
an additional 24 hours, and processed for Noxa immunoblotting.
GAPDH was used as a loading control. Protein size in kilodaltons
(kDa) is also shown.
(TIF)
Figure S4 Bortezomib induces a time- and dose-de-
pendent increase in Noxa protein levels. HCT116 cells
were treated with increasing concentrations of bortezomib and
analyzed for Noxa protein expression (upper panel). HCT116 cells
were treated with 20 nM bortezomib, collected at the indicated
timepoints and processed for immunoblotting for the indicated
proteins (lower panel). While Noxa is induced already after three
hours, cleaved PARP and caspase 3 immunoblots demonstrate
that apoptosis is not properly executed until after 24 hours of
treatment. GAPDH was used as a loading control. Protein size in
kilodaltons (kDa) is also shown.
(TIF)
Figure S5 HCT116 cells were transfected with empty
vector (pcDNA) or with a Noxa overexpression construct
(pcDNA-Noxa). Protein extracts were analyzed for Noxa and
GAPDH levels by immunoblotting. Protein size in kilodaltons
(kDa) is also shown.
(TIF)
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apoptosis was assessed by Annexin V/PI staining and FACS (upper panel). Cells were also collected and processed for immunoblotting for GAPDH and
Noxa to demonstrate efficiency of siRNA knockdown (lower panel). Protein size in kilodaltons (kDa) is shown. (B) HCT116 cells were transfected with
the indicated constructs and oligos. Samples were either left untreated (left panel) or treated with 20 nM bortezomib (right panel) and were
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